{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '205270', 'All AEs will be collected from the start of study treatment until the follow-up', 'visit at the time points specified in the SoA (Section 2).', 'Medical occurrences that begin before the start of study treatment but after', 'obtaining informed consent will be recorded on the Medical History/Current', 'Medical Conditions section of the eCRF not the AE section.', 'All SAEs will be recorded and reported to GSK or designee immediately and', 'under no circumstance should this exceed 24 hours, as indicated in Section 12.4', '(Appendix 3). The investigator will submit any updated SAE data to GSK', 'within 24 hours of it being available.', 'Investigators are not obligated to actively seek AEs or SAEs in former study', 'participants. However, if the investigator learns of any SAE, including a death,', 'at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study treatment or study', 'participation, the investigator must promptly notify GSK.', 'The method of recording, evaluating, and assessing causality of AEs and SAEs', 'and the procedures for completing and transmitting SAE reports are provided in', 'Section 12.4 (Appendix 3).', '9.3.2.', 'Method of Detecting AEs and SAEs', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended', 'and non-leading verbal questioning of the participant is the preferred method to inquire', 'about AE occurrence.', '9.3.3.', 'Follow-up of AEs and SAEs', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All SAEs and non-serious AEs of special', 'interest (as defined in Section 9.3.6), will be followed until the event is resolved,', 'stabilized, otherwise explained, or the participant is lost to follow-up (as defined in', 'Section 8.3). Further information on follow-up procedures is given in Section 12.4', '(Appendix 4).', '9.3.4.', 'Regulatory Reporting Requirements for SAEs', 'Prompt notification by the investigator to GSK of an SAE related to placebo or', 'daprodustat is essential so that legal obligations and ethical responsibilities', 'towards the safety of participants and the safety of a study treatment under', 'clinical investigation are met.', 'GSK has a legal responsibility to notify both the local regulatory authority and', 'other regulatory agencies about the safety of a study treatment under clinical', 'investigation. GSK will comply with country-specific regulatory requirements', 'relating to safety reporting to the regulatory authority, Institutional Review', 'Boards (IRB)/Independent Ethics Committees (IEC), and investigators.', '56']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Investigator safety reports must be prepared for suspected unexpected serious', 'adverse reactions (SUSAR) according to local regulatory requirements and GSK', 'policy and forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing an SAE or', 'other specific safety information (e.g., summary or listing of SAE) from GSK', \"will review and then file it along with the Investigator's Brochure[IE\", 'GlaxoSmithKline Document number RM2008/00267/07] and will notify the', 'IRB/IEC, if appropriate according to local requirements.', '9.3.5.', 'Events Referred to the Clinical Events Committee (CEC)', 'Investigators should refer any event suspected to be one of the events below to the CEC', 'for adjudication, See CEC Site Manual for full scope of reporting requirements:', 'All-cause mortality (CV and non-CV mortality)', 'Non-fatal myocardial infarction (MI)', 'Non-fatal stroke', 'Hospitalization for HF', 'Thromboembolic events (vascular access thrombosis, deep vein thrombosis,', 'pulmonary embolism)', 'Events referred to the CEC will be subjected to blinded adjudication using pre-specified', 'diagnostic criteria.', 'When the investigator-reported event and the CEC assessment by the committee differ,', \"the committee's decision will be considered final. The detailed descriptions of the\", 'endpoint definitions used for adjudication are contained within the CEC Charter', '(available on request).', 'Source documentation required to support the adjudication of the events is described in', 'the CEC site manual.', '9.3.6.', 'Other Cardiovascular (CV) Events', 'GSK has identified other CV events of interest for all clinical studies. Investigators will', 'be required to fill out the specific CV event page of the eCRF for the following CV AEs', 'and SAEs or any event that may potentially be one of the categories listed:', 'Arrhythmias', 'Pulmonary hypertension (also an AE of special interest see Section 9.3.7 for further', 'details).', 'Valvulopathy', 'Revascularization', '57']\n\n###\n\n", "completion": "END"}